**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 39129**

**Manuscript Type: REVIEW**

**Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells**

Li TT *et al*. Blood biomarkers in gastric cancer

Ting-Ting Li, Hao Liu, Jiang Yu, Guang-Yao Shi, Li-Ying Zhao, Guo-Xin Li

**Ting-Ting Li, Hao Liu, Jiang Yu, Li-Ying Zhao, Guo-Xin Li,** Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China

**Guang-Yao Shi**, Division of Cardiology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China

**ORCID number:** Ting-Ting Li (0000-0001-9209-0602); Hao Liu (0000-0003-1227-2954); Jiang Yu (0000-0003-0086-1604); Guang-Yao Shi (0000-0002-2571-9252); Li-Ying Zhao (0000-0002-3723-5626); Guo-Xin Li (0000-0003-2773-7048).

**Author contributions:** Li TT, Liu H and Yu J contributed equally to the design and preparation of this study and should be considered co-first authors; Yu J and Li GX designed the research; Li TT and Liu H contributed to data acquisition and writing of article; Zhao LY and Shi GY contributed to data analysis; Liu H, Yu J and Li GX contributed to editing, reviewing and final approval of article.

**Supported by** the grants from the State's Key Project of Research and Development Plan, No. 2017YFC0108300, and No. 2017YFC0108301; National Natural Science Foundation of China, No. 81672446; Guangdong Provincial Science and Technology Key Project, No. 2014A020215014; Research Fund of Public Welfare in the Health Industry of the National Health and Family Planning Commission of China, No. 201402015; the Guangdong Provincial Natural Science Foundation, No. 2016A030313843; the Southern Medical University Clinical Research Start-Up Project, No. LC2016ZD003; and the Key Clinical Specialty Discipline Construction Program, No. [2011]170.

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Guo-xin Li, MD, PhD**, **Professor**, Department of General Surgery, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou 510515, Guangdong Province, China. gzliguoxin@163.com

**Telephone:** +86-20-61641681

**Fax:** +86-20-62787626

**Received:** April 3, 2018

**Peer-review started:** April 4, 2018

**First decision:** April 19, 2018

**Revised:** April 27, 2018

**Accepted:** May 18, 2018

**Article in press:**

**Published online:**

**Abstract**

Gastric cancer (GC), with its high incidence and mortality rates, is a highly fatal cancer that is common in East Asia particularly in China. Its recurrence and metastasis are the main causes of its poor prognosis. Circulating tumor cells (CTCs) or other blood biomarkers that are released into the circulating blood stream by tumors are thought to play a crucial role in the recurrence and metastasis of gastric cancer. Therefore, the detection of CTCs and other blood biomarkers has an important clinical significance; in fact, they can help predict the prognosis, assess the staging, monitor the therapeutic effects and determine the drug susceptibility. Recent research has identified many blood biomarkers in GC, such as various serum proteins, autoantibodies against tumor associated antigens, and cell-free DNAs. The analysis of CTCs and circulating cell-free tumor DNA (ctDNA) in the peripheral blood of patients with gastric cancer is called as liquid biopsy. These blood biomarkers provide the disease status for individuals and have clinical meaning. In this review, we focus on the recent scientific advances regarding CTCs and other blood biomarkers, and discuss their origins and clinical meaning.

**Key words:** Gastric cancer; Biomarker; Circulating tumor cells; Autoantibodies; Cell-free DNA

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** As liquid biopsy, the detection of circulating tumor cells (CTCs) and other blood biomarkers have their certain clinical significance. In this review, we focus on the recent scientific advances of CTCs and some other blood biomarkers, and discuss their origin and clinical usefulness.

Li TT, Liu H, Yu J, Shi GY, Zhao LY, Li GX. Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells. *World J Gastroenterol* 2018; In press

**INTRODUCTION**

Gastric cancer (GC) ranks as the fifth most common malignant tumor and the third leading cause of cancer deaths, with more than 951000 new cases and 723000 deaths estimated per year (GLOBOCAN 2012)[[1](#_ENREF_1)]. Despite the development of diagnostic techniques, surgical techniques and perioperative management in recent years, the prognostic outcomes for GC remain poor. Because early stage GC tends to be asymptomatic and because mass screening is not popular, most patients in China are diagnosed at an advanced stage[[2](#_ENREF_2)]. The prognosis of peritoneal metastasis from gastric cancer is very poor. In addition, the median survival is 4-12 months, and the 5-year actuarial survival rate of patients with peritoneal metastasis is less than 5%[[3](#_ENREF_3),[4](#_ENREF_4)]. Therefore, finding useful diagnostic and monitoring tools for gastric cancer patients should be considered as the most important clinical objectives.

A “liquid biopsy” for gastric cancer patients is used to detect physiological indicators or parameters in the serum; the procedure is less invasive than an endoscopic or surgical biopsy, and it allows practitioners to detect the disease earlier and visualize the dynamics and development of gastric tumors, as well as treatment efficiency and chemotherapy resistance. Carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9) and cancer antigen 72-4 (CA72-4) are regarded as clinically popular gastrointestinal tumor biomarkers. However, their positivity rates are less than 40% in GC patients, and the sensitivity and specificity of these blood biomarkers are not sufficient[[5](#_ENREF_5),[6](#_ENREF_6)]. Indeed, if a blood biomarker is to be used in a population-based screening program, it should be reliable in repeated applications and easily measurable in blood serum or plasma by common laboratory equipment. Moreover, it should be present in the bloodstream before the onset of manifestations and clinical symptoms, be able to distinguish between cancer and inflammation and have high positive predictive value for malignant tumors. Therefore, there is an urgent need to identify more precise and effective blood biomarkers to provide optimal management for GC patients; these blood biomarkers should be able to provide early detection, clinical staging, therapy response monitoring, and prognosis for GC.

Cells can be released into the blood stream from the original tumor and/or corresponding distant metastatic sites. These circulating tumor cells (CTCs) could be collected and detected through respective technologies according to their physical and biologic features. CTCs from cancer patients may be considered as a type of real-time “liquid biopsy” that could provide real-time information about the cancer status. CTCs have already been accepted by the FDA as a prognostic biomarker for monitoring patients with breast, prostate and colorectal cancer[[7](#_ENREF_7)]. Currently, the concept of “liquid biopsy” has also been accepted for the clinical application of evaluating ctDNAs that apoptotic and necrotic cancer cells discharge into the blood circulation[[8](#_ENREF_8)]. As we know, there are numerous genetic and epigenetic aberrations that could activate oncogenes and promote tumor progression. Therefore, we have developed sensitive molecular assays for the detection of ctDNAs in the blood plasma to find tumor-specific aberrations. Moreover, several autoantibodies against specific tumor associated antigens (TAAs) that are expressed by cancer cells and can be detected in the blood plasma more than five years prior to diagnosis have already been identified[[9](#_ENREF_9)]. Therefore, CTC, ctDNAs and autoantibodies could become potential blood biomarkers for gastric cancer[[10](#_ENREF_10)].

In this article, we focus on the clinical applications of CTC, ctDNAs and autoantibodies after a brief introduction of the biology and detection technologies, and we explore the future prospects of blood biomarkers in gastric cancer patients.

**THE BIOLOGY BEHIND CTCs**

The cancer cells that are released from the original tumor or corresponding distant metastatic sites into the circulating blood are called CTCs. However, these epithelial tumor cells cannot stay in the harsh conditions of the bloodstream, and it is possible that CTCs are selected through these harsh conditions[[11](#_ENREF_11)]. This proposal is consistent with the phenomenon that there are many apoptotic or fragmented CTCs in the peripheral blood stream of cancer patients[[12](#_ENREF_12)]. The treacherous journey through the vasculature is necessary for the spread of cancer cells to additional sites. CTCs are closely associated with activated platelets and macrophages[[13](#_ENREF_13)]. Moreover, the transference of metastatic cancer cells into the circulating blood often relies on various chemokines, such as CCR4, CCR7, CCR9, and CXCR4, which guide the cancer cells across the blood vessels[[14](#_ENREF_14)]. Even a few months or years after primary tumor removal, CTCs can be detected in the peripheral bloodstream of cancer patients, which indicates that cancer cells can be released into the circulation from other metastatic sites[[15](#_ENREF_15),[16](#_ENREF_16)]. However, how these CTCs give rise to tumor metastasis and progression remains unclear. Future comparative genomic analyses of primary carcinoma and metastatic specimens along with CTCs from the same patient might provide more insight (shown in Figure 1).

Currently, CTCs are often detected by epithelial markers such as epithelial cell adhesion molecule (EpCAM) and cytokeratins (CKs), which are not expressed on the surface of blood cells and distinguish CTCs from the masses of blood cells[[17](#_ENREF_17)]. Epithelial cancer cells can make an epithelial-to-mesenchymal transition (EMT) that leads to decreased epithelial marker expression and enhanced plasticity and migration and invasion capacity. The CTCs that undergo EMT could be resistant to anoikis, which are necessary for the survival and dissemination of CTCs[[17](#_ENREF_17)]. It has been previously indicated that EMT might particularly affect the stemness of tumor cells[[18](#_ENREF_18)]. CTCs that undergo EMT might escape detection by EpCAM-based collection methods, such as the CellSearch system. Our previous study explored mesenchymal markers (Vimentin and Twist) to identify the mesenchymal phenotypes of CTCs in the bloodstream and their relevance to therapy responses[[19](#_ENREF_19)].

**TECHNOLOGIES FOR CTCs DETECTION**

The evolution of various technologies to enrich and detect CTCs has been considerable, even resulting in the detection and verification of new CTC markers[[17](#_ENREF_17)]. It is vital that we pay close attention to the biological characteristics of tumor cells dissemination and potential stem cell like properties that are affected by EMT, particularly in the field of CTCs[[18](#_ENREF_18)]. Therefore, many companies have optimized their devices to select and detect CTCs that have undergone EMT[[17](#_ENREF_17)].

After an enrichment step, we could greatly increase the concentration of CTCs and enable the easy detection of even a single tumor cell. Then, CTCs can be detected by different techniques. In theory, CTCs could be positively or negatively chosen based on physical features (*e.g*., size, density, deforming character, and electric charges) and biologic features (*e.g.*, the expression of protein markers). The enrichment of positively or negatively chosen CTCs could also be achieved based on particular combinations of physical and biologic features in a device. Then, the CTCs could be detected through immunologic, molecular, and/or functional assays. Recently, increasing numbers of research teams have attempted functional tests using cultures and xenografts of CTCs[[20](#_ENREF_20),[21](#_ENREF_21)]. *In vitro* and *in vivo* CTCs models can be applied to detect individualized drug susceptibility. However, the ability to establish CTCs cultures and xenografts of CTCs should be improved to design personalized medicine. Currently, hundreds or thousands of CTCs are required to construct cancer cell cultures or xenografts, which limits this approach to individual therapy (shown in Figure 1).

The new technical developments that we focus on are based on new discoveries in CTC biology. A lack of knowledge has hindered the development of the application of CTCs for clinical diagnosis. However, new significant perspectives regarding the biological meaning of CTCs and various revolutionary techniques have been reported[[22](#_ENREF_22)]. We believe that equipment for the combined collection, detection, and characterization of CTCs will soon be applied clinically.

**CTCs AS AN INDICATOR FOR GC RECURRENCE AND METASTASIS**

Recurrence and metastasis not only predict clinical outcomes but also affect the quality of life of GC patients. They are the most critical factors in the treatment of GC. It was originally thought that incomplete surgical resection resulted in recurrence and metastasis after the operative treatment of GC; therefore, extensive radical resection was applied. However, this procedure was not successful, indicating that there are other possible reasons for recurrence and metastasis. Some researchers found that tumor cells could be released into the bloodstream at the early stage of solid tumors (*e.g.*, breast, colon, lung, and gastric cancer)[[7](#_ENREF_7)]. Therefore, CTCs may also play a vital role in monitoring the dissemination of gastric cancer and guiding the treatment of GC patients with recurrence and metastasis.

As summarized in Table 1, many studies have reported the clinical value of CTCs as prognostic indicators by different detection methods, including the CellSearch system, RT-PCR/qRT-PCR, and FISH. Uenosono *et al*[[23](#_ENREF_23)] detected CTCs using the CellSearch system in 251 gastric cancer patients and found that the overall survival (OS) was obviously lower in patients with CTCs than in patients without CTCs (*P* < 0.0001). Subgroup analysis revealed that the relapse-free survival and OS were significantly lower in patients with CTCs than in patients without CTCs in the resection group (*P* < 0.0001). In a prospective study, Matsusaka *et al*[[24](#_ENREF_24)] also assessed the correlation between CTCs detected by the CellSearch system and chemotherapy and clinical outcomes. They found that GC patients with at least 4 CTCs at 2 and 4 wk after the onset of chemotherapy had an obviously shorter overall survival and progression-free survival than the patients with less than 4 CTCs. However, the CTCs levels at baseline (*i.e.*, before chemotherapy) had no positive correlation with the clinical outcomes. These findings may indicate that the treatment response of CTCs is correlated with clinical outcomes. The number of studies using RT-PCR/qRT-PCR methods is relatively small. However, Mimori *et al*[[25](#_ENREF_25)] detected a candidate marker, the membrane type 1 matrix metalloproteinase (MT1-MMP) mRNA level, in more than 800 GC patients. This marker was chosen based on the results of a cDNA microarray analysis, and its correlation with prognosis was subsequently validated using qRT-PCR. As a consequence, the MT1-MMP mRNA level in the peripheral blood may be an independent prognostic indicator of recurrence and metastasis in GC patients (*P* = 0.0018).

Taken together, these studies indicate that CTCs result in GC recurrence and metastasis and may act as vital therapeutic targets for the treatment of GC recurrence and metastasis after radical resection.

**OTHER POTENTIAL BLOOD BIOMARKERS**

***Cell-free nucleic acids***

Tumor DNA can be released into the blood stream from the primary tumors, circulating tumor cells, or metastases of cancer patients. The majority of circulating cell-free tumor DNAs (ctDNAs) come from apoptotic or necrotic cancer cells that release fragmented DNA into the circulating blood. Dying nonmalignant host cells can also release cell-free DNAs (cfDNAs) into the circulating blood. These normal cfDNAs can dilute the ctDNAs concentrations in cancer patients, particularly in circumstances when tissue-damaging procedures, including surgery, chemotherapy, or radiotherapy, were carried out. Even though the length of DNA fragments might provide some information about the derivation of cfDNAs[[26](#_ENREF_26),[27](#_ENREF_27)], we should further explore the biological features of the ctDNAs in the circulating blood. Several studies have indicated that ctDNAs can even be absorbed by host cells, and this uptake can affect the biology of these host cells[[28](#_ENREF_28),[29](#_ENREF_29)]. Thus, ctDNAs may be indicated as a new target for anti-tumor treatment in order to dilute this type of oncogenic DNA, an idea proposed decades ago[[30](#_ENREF_30)]. Several clinical applications of ctDNAs have been used for gastric cancer. ctDNAs is not only a tool for the early detection of cancer but also a prognostic or predictive factor (shown in Table 2).

Among previous studies of ctDNAs in GC patients, we found that some studies focused on the concentration of ctDNAs. In these studies, the housekeeping gene, beta-actin[[31](#_ENREF_31)], and a non-coding DNA sequence, ALU[[32](#_ENREF_32)], were assessed. By comparison, the most widely used method for detecting ctDNAs is the measurement of methylated DNA in the plasma or serum; this measurement is often performed with methylation specific-PCR (MSP) or quantitative methylation specific-PCR (qMSP) assays. With the advances in technology and verification of more sensitive and specific genes, evidence has accumulated in this field. Comprehensive analyses using methylation CpG island microarray have indicated the possibility of more meaningful genes for measuring methylated DNA. Furthermore, Ling *et al*[[33](#_ENREF_33)] have shown the effective application of methylated XAF1 DNA. This DNA could be used as a diagnostic or prognostic biomarker with high specificity and sensitivity. In addition to mutation analyses, gene amplification appears to provide relevant blood biomarkers. Park *et al*[[34](#_ENREF_34)] found that the combination of plasma HER2 and MYC concentrations to diagnose GC had a sensitivity and specificity of 69% and 92%, respectively. To determine the effect of sequencing methods upon the overall diagnostic accuracy, Shoda et al compared qPCR[[35](#_ENREF_35)] and digital droplet PCR (ddPCR)[[36](#_ENREF_36)] for detecting the HER2 amplification ratio in 60 patients with GC. A correlation between the plasma and tissue HER2 amplification ratios was observed by ddPCR (ρ= 0.424, 95% CI 0.125–0.652, p= 0.00721).

**C*ancer-associated autoantibodies***

IgG Autoantibodies against specific tumor associated antigens (TAAs) can be detected in the blood more than five years prior to a clinical diagnosis of cancer, thus indicating their important role in the prognosis of early-stage cancer[[37](#_ENREF_37),[38](#_ENREF_38)]. Additionally, autoantibodies have other promising biomarker qualities: they can be detected in every type of tumor that has ever been tested[[39](#_ENREF_39),[40](#_ENREF_40)] and they are very stable and have antigen specificity. Assessing the autoantibody response against TAAs with multiplex immunoassays is supposed to be viable, and this method might make them clinically applicable.

To the best of our knowledge, ten studies have reported the clinical diagnosis values of diverse GC associated autoantibodies or their combinations (shown in Table 2). In these studies, the recognized biomarkers can distinguish GC patients from healthy controls with comparatively excellent specificity (87-100%), but discrepant sensitivity (19.3%-98.9%). There are three studies that described the AUC: Zhou *et al*[[41](#_ENREF_41)] reported that autoantibodies against seven TAAs could distinguish GC patients from healthy subjects with an AUC of 0.73. Zayakin *et al*[[42](#_ENREF_42)] showed that 45 autoantibodies could distinguish GC patients from healthy subjects with an AUC of 0.79, while Meistere *et al*[[43](#_ENREF_43)] reported an AUC of 0.60. These ten studies of autoantibodies in GC vary greatly regarding the number of autoantibodies measured (ranging from 2 to 102), the techniques used to detect the autoantibodies, the definition of suitable control groups, and the methods used to normalize the data and define cut-off values. Taken together, these factors may greatly hinder the clinical application of the reported biomarkers.

In general, measuring autoantibodies against TAAs has been reported to have excellent specificity but general sensitivity, which would hamper its use in clinical medicine. The biological mechanisms underlying the limitations of autoantibody sensitivity are currently unknown. Additionally, the heterogeneity of TAAs among cancer patients is very high, and one cancer-specific autoantibody usually has a low probability of detection and is thus unlikely to have statistical significance. Therefore, recently published studies are likely to be statistically inefficient. However, diagnostic biomarker panels result in the low repeatability of initial results and reduce the diagnostic value of autoantibodies, but this issue could be remedied by analyzing combinations with good statistical significance.

**PERSPECTIVES**

In general, the field of CTCs, ctDNAs and autoantibodies is stimulating discovery regarding the tumor recurrence and metastasis, but it is still in the early stages. The transformation of these blood biomarkers into conventional clinical indicators is hampered by the absence of consistency among different technical methods. The CellSearch system is the first standardized semi-automatic technique approved by the FDA to enrich and detect CTCs in patients with breast, prostate or colorectal cancer. Many studies have shown that the results of CTCs detection with the CellSearch system could serve as a clinical prognostic and therapeutic effectiveness indicator for these cancers. Recently, a few studies have shown that detection of CTCs in GC patients using the CellSearch system could be used for staging, predicting patients’ overall survival and evaluating the treatment effectiveness. However, large-scale clinical studies are needed to further validate the important role of CTCs and to explore an applicable cut-off value for the CTCs score in GC patients.

Although various methods and techniques have been recommended for ultimately establishing an applicable, sensitive and real-time monitoring system using circulating blood, few methods can currently be applied in clinical practice. Large-scale clinical trials and further exploration of the biology and significance of blood biomarkers might solve the associated problems and improve their application as blood biomarkers. Therefore, the exploration of revolutionary blood biomarkers, such as CTCs, ctDNAs and autoantibodies, could provide many advantages for gastric cancer patients and improve their clinical outcomes in the future.

**REFERENCES**

1 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

2 **Chen W**, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016; **66**: 115-132 [PMID: 26808342 DOI: 10.3322/caac.21338]

3 **Sarela AI**, Miner TJ, Karpeh MS, Coit DG, Jaques DP, Brennan MF. Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. *Ann Surg* 2006; **243**: 189-195 [PMID: 16432351 DOI: 10.1097/01.sla.0000197382.43208.a5]

4 **Lasithiotakis K**, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. *Anticancer Res* 2014; **34**: 2079-2085 [PMID: 24778009]

5 **Li Y**, Yang Y, Lu M, Shen L. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. *Hepatogastroenterology* 2011; **58**: 2166-2170 [PMID: 22024091 DOI: 10.5754/hge11753]

6 **Ishigami S**, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, Iwashige H, Tokushige M, Watanabe T, Takao S, Aikou T. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. *J Clin Gastroenterol* 2001; **32**: 41-44 [PMID: 11154168]

7 **Pantel K**, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. *Trends Mol Med* 2010; **16**: 398-406 [PMID: 20667783 DOI: 10.1016/j.molmed.2010.07.001]

8 **Diaz LA Jr**, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. *J Clin Oncol* 2014; **32**: 579-586 [PMID: 24449238 DOI: 10.1200/JCO.2012.45.2011]

9 **Turk MJ**, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN. Multiple pathways to tumor immunity and concomitant autoimmunity. *Immunol Rev* 2002; **188**: 122-135 [PMID: 12445286]

10 **Haber DA**, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. *Cancer Discov* 2014; **4**: 650-661 [PMID: 24801577 DOI: 10.1158/2159-8290.CD-13-1014]

11 **Kang Y**, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. *Cancer Cell* 2013; **23**: 573-581 [PMID: 23680145 DOI: 10.1016/j.ccr.2013.04.017]

12 **Larson CJ**, Moreno JG, Pienta KJ, Gross S, Repollet M, O'hara SM, Russell T, Terstappen LW. Apoptosis of circulating tumor cells in prostate cancer patients. *Cytometry A* 2004; **62**: 46-53 [PMID: 15472900 DOI: 10.1002/cyto.a.20073]

13 **Smith HA**, Kang Y. The metastasis-promoting roles of tumor-associated immune cells. *J Mol Med (Berl)* 2013; **91**: 411-429 [PMID: 23515621 DOI: 10.1007/s00109-013-1021-5]

14 **Bonecchi R**, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. *Front Biosci (Landmark Ed)* 2009; **14**: 540-551 [PMID: 19273084]

15 **Meng S**, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW. Circulating tumor cells in patients with breast cancer dormancy. *Clin Cancer Res* 2004; **10**: 8152-8162 [PMID: 15623589 DOI: 10.1158/1078-0432.CCR-04-1110]

16 **Müller V**, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Jänicke F, Pantel K. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. *Clin Cancer Res* 2005; **11**: 3678-3685 [PMID: 15897564 DOI: 10.1158/1078-0432.CCR-04-2469]

17 **Alix-Panabières C**, Pantel K. Challenges in circulating tumour cell research. *Nat Rev Cancer* 2014; **14**: 623-631 [PMID: 25154812 DOI: 10.1038/nrc3820]

18 **Mani SA**, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008; **133**: 704-715 [PMID: 18485877 DOI: 10.1016/j.cell.2008.03.027]

19 **Li TT**, Liu H, Li FP, Hu YF, Mou TY, Lin T, Yu J, Zheng L, Li GX. Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response. *World J Gastroenterol* 2015; **21**: 13259-13267 [PMID: 26715808 DOI: 10.3748/wjg.v21.i47.13259]

20 **Pantel K**, Alix-Panabières C. Functional Studies on Viable Circulating Tumor Cells. *Clin Chem* 2016; **62**: 328-334 [PMID: 26637479 DOI: 10.1373/clinchem.2015.242537]

21 **Alix-Panabières C**, Pantel K. Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. *Expert Rev Mol Diagn* 2015; **15**: 1411-1417 [PMID: 26390240 DOI: 10.1586/14737159.2015.1091729]

22 **Pantel K**, Speicher MR. The biology of circulating tumor cells. *Oncogene* 2016; **35**: 1216-1224 [PMID: 26050619 DOI: 10.1038/onc.2015.192]

23 **Uenosono Y**, Arigami T, Kozono T, Yanagita S, Hagihara T, Haraguchi N, Matsushita D, Hirata M, Arima H, Funasako Y, Kijima Y, Nakajo A, Okumura H, Ishigami S, Hokita S, Ueno S, Natsugoe S. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. *Cancer* 2013; **119**: 3984-3991 [PMID: 23963829 DOI: 10.1002/cncr.28309]

24 **Matsusaka S**, Chìn K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Mizunuma N, Hatake K. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. *Cancer Sci* 2010; **101**: 1067-1071 [PMID: 20219073 DOI: DOI]

25 **Mimori K**, Fukagawa T, Kosaka Y, Ishikawa K, Iwatsuki M, Yokobori T, Hirasaki S, Takatsuno Y, Sakashita H, Ishii H, Sasako M, Mori M. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. *Ann Surg Oncol* 2008; **15**: 2934-2942 [PMID: 18661187 DOI: 10.1245/s10434-008-9916-z]

26 **Heitzer E**, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Höfler G, Eisner F, Petru E, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. *Int J Cancer* 2013; **133**: 346-356 [PMID: 23319339 DOI: 10.1002/ijc.28030]

27 **Lo YM**, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. *Am J Hum Genet* 1999; **64**: 218-224 [PMID: 9915961 DOI: 10.1086/302205]

28 **Schwarzenbach H**, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. *Nat Rev Cancer* 2011; **11**: 426-437 [PMID: 21562580 DOI: 10.1038/nrc3066]

29 **Trejo-Becerril C**, Pérez-Cárdenas E, Taja-Chayeb L, Anker P, Herrera-Goepfert R, Medina-Velázquez LA, Hidalgo-Miranda A, Pérez-Montiel D, Chávez-Blanco A, Cruz-Velázquez J, Díaz-Chávez J, Gaxiola M, Dueñas-González A. Cancer progression mediated by horizontal gene transfer in an in vivo model. *PLoS One* 2012; **7**: e52754 [PMID: 23285175 DOI: 10.1371/journal.pone.0052754]

30 **DE LAMIRANDE G**. Action of deoxyribonuclease and ribonuclease on the growth of Ehrlich ascites carcinoma in mice. *Nature* 1961; **192**: 52-54 [PMID: 13884299]

31 **Sai S**, Ichikawa D, Tomita H, Ikoma D, Tani N, Ikoma H, Kikuchi S, Fujiwara H, Ueda Y, Otsuji E. Quantification of plasma cell-free DNA in patients with gastric cancer. *Anticancer Res* 2007; **27**: 2747-2751 [PMID: 17695442]

32 **Park JL**, Kim HJ, Choi BY, Lee HC, Jang HR, Song KS, Noh SM, Kim SY, Han DS, Kim YS. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. *Oncol Lett* 2012; **3**: 921-926 [PMID: 22741019 DOI: 10.3892/ol.2012.592]

33 **Ling ZQ**, Lv P, Lu XX, Yu JL, Han J, Ying LS, Zhu X, Zhu WY, Fang XH, Wang S, Wu YC. Circulating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer. *PLoS One* 2013; **8**: e67195 [PMID: 23826230 DOI: 10.1371/journal.pone.0067195]

34 **Park KU**, Lee HE, Nam SK, Nam KH, Park DJ, Kim HH, Kim WH, Lee HS. The quantification of HER2 and MYC gene fragments in cell-free plasma as putative biomarkers for gastric cancer diagnosis. *Clin Chem Lab Med* 2014; **52**: 1033-1040 [PMID: 24670359 DOI: 10.1515/cclm-2013-0988]

35 **Shoda K**, Masuda K, Ichikawa D, Arita T, Miyakami Y, Watanabe M, Konishi H, Imoto I, Otsuji E. HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. *Gastric Cancer* 2015; **18**: 698-710 [PMID: 25322965 DOI: 10.1007/s10120-014-0432-5]

36 **Shoda K**, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, Arita T, Konishi H, Komatsu S, Shiozaki A, Kakihara N, Okamoto K, Taniguchi H, Imoto I, Otsuji E. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. *Gastric Cancer* 2017; **20**: 126-135 [PMID: 26874951 DOI: 10.1007/s10120-016-0599-z]

37 **Chapman C**, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J. Autoantibodies in breast cancer: their use as an aid to early diagnosis. *Ann Oncol* 2007; **18**: 868-873 [PMID: 17347129 DOI: 10.1093/annonc/mdm007]

38 **Zhong L**, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. *J Thorac Oncol* 2006; **1**: 513-519 [PMID: 17409910]

39 **Preuss KD**, Zwick C, Bormann C, Neumann F, Pfreundschuh M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. *Immunol Rev* 2002; **188**: 43-50 [PMID: 12445280]

40 **Scanlan MJ**. Identification of human tumor antigens by serological analysis of recombinant cDNA expression libraries (SEREX). *Curr Protoc Immunol* 2005; **Chapter 20**: Unit 20.7 [PMID: 18432945 DOI: 10.1002/0471142735.im2007s65]

41 **Zhou SL**, Ku JW, Fan ZM, Yue WB, Du F, Zhou YF, Liu YL, Li Y, Tang S, Hu YL, Hu XP, Hou ZC, Liu J, Liu Y, Feng XS, Wang LD. Detection of autoantibodies to a panel of tumor-associated antigens for the diagnosis values of gastric cardia adenocarcinoma. *Dis Esophagus* 2015; **28**: 371-379 [PMID: 24612004 DOI: 10.1111/dote.12206]

42 **Zayakin P**, Ancāns G, Siliņa K, Meistere I, Kalniņa Z, Andrejeva D, Endzeliņš E, Ivanova L, Pismennaja A, Ruskule A, Doniņa S, Wex T, Malfertheiner P, Leja M, Linē A. Tumor-associated autoantibody signature for the early detection of gastric cancer. *Int J Cancer* 2013; **132**: 137-147 [PMID: 22684876 DOI: 10.1002/ijc.27667]

43 **Meistere I**, Werner S, Zayakin P, Siliņa K, Rulle U, Pismennaja A, Šantare D, Kikuste I, Isajevs S, Leja M, Kupčinskas L, Kupčinskas J, Jonaitis L, Wu CY, Brenner H, Linē A, Kalniņa Z. The Prevalence of Cancer-Associated Autoantibodies in Patients with Gastric Cancer and Progressive Grades of Premalignant Lesions. *Cancer Epidemiol Biomarkers Prev* 2017; **26**: 1564-1574 [PMID: 28768706 DOI: 10.1158/1055-9965.EPI-17-0238]

44 **Yeh KH**, Chen YC, Yeh SH, Chen CP, Lin JT, Cheng AL. Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 (K19)--possible clinical significance in advanced gastric cancer. *Anticancer Res* 1998; **18**: 1283-1286 [PMID: 9615802]

45 **Miyazono F**, Natsugoe S, Takao S, Tokuda K, Kijima F, Aridome K, Hokita S, Baba M, Eizuru Y, Aikou T. Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. *Ann Surg* 2001; **233**: 189-194 [PMID: 11176124]

46 **Sumikura S**, Ishigami S, Natsugoe S, Miyazono F, Tokuda K, Nakajo A, Okumura H, Matsumoto M, Hokita S, Aikou T. Disseminated cancer cells in the blood and expression of sialylated antigen in gastric cancer. *Cancer Lett* 2003; **200**: 77-83 [PMID: 14550955]

47 **Friederichs J**, Gertler R, Rosenberg R, Nahrig J, Führer K, Holzmann B, Dittler HJ, Dahm M, Thorban S, Nekarda H, Siewert JR. Prognostic impact of CK-20-positive cells in peripheral venous blood of patients with gastrointestinal carcinoma. *World J Surg* 2005; **29**: 422-428 [PMID: 15770378 DOI: 10.1007/s00268-004-7662-3]

48 **Illert B**, Fein M, Otto C, Cording F, Stehle D, Thiede A, Timmermann W. Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosis. *Scand J Gastroenterol* 2005; **40**: 843-849 [PMID: 16109661 DOI: 10.1080/00365520510015557]

49 **Seo JH**, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, Lee SW, Choi JH, Park YT, Mok YJ, Kim CS, Kim JS. Follow-up study of peripheral blood carcinoembryonic antigen mRNA using reverse transcription-polymerase chain reaction as an early marker of clinical recurrence in patients with curatively resected gastric cancer. *Am J Clin Oncol* 2005; **28**: 24-29 [PMID: 15685031]

50 **Uen YH**, Lin SR, Wu CH, Hsieh JS, Lu CY, Yu FJ, Huang TJ, Wang JY. Clinical significance of MUC1 and c-Met RT-PCR detection of circulating tumor cells in patients with gastric carcinoma. *Clin Chim Acta* 2006; **367**: 55-61 [PMID: 16403482 DOI: 10.1016/j.cca.2005.11.013]

51 **Wu CH**, Lin SR, Hsieh JS, Chen FM, Lu CY, Yu FJ, Cheng TL, Huang TJ, Huang SY, Wang JY. Molecular detection of disseminated tumor cells in the peripheral blood of patients with gastric cancer: evaluation of their prognostic significance. *Dis Markers* 2006; **22**: 103-109 [PMID: 16788243]

52 **Wu CH**, Lin SR, Yu FJ, Wu DC, Pan YS, Hsieh JS, Huang SY, Wang JY. Development of a high-throughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers. *Int J Cancer* 2006; **119**: 373-379 [PMID: 16477642 DOI: 10.1002/ijc.21856]

53 **Pituch-Noworolska A**, Kolodziejczyk P, Kulig J, Drabik G, Szczepanik A, Czupryna A, Popiela T, Zembala M. Circulating tumour cells and survival of patients with gastric cancer. *Anticancer Res* 2007; **27**: 635-640 [PMID: 17348453]

54 **Hiraiwa K**, Takeuchi H, Hasegawa H, Saikawa Y, Suda K, Ando T, Kumagai K, Irino T, Yoshikawa T, Matsuda S, Kitajima M, Kitagawa Y. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. *Ann Surg Oncol* 2008; **15**: 3092-3100 [PMID: 18766405 DOI: 10.1245/s10434-008-0122-9]

55 **Koga T**, Tokunaga E, Sumiyoshi Y, Oki E, Oda S, Takahashi I, Kakeji Y, Baba H, Maehara Y. Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR. *Hepatogastroenterology* 2008; **55**: 1131-1135 [PMID: 18705345]

56 **Yie SM**, Lou B, Ye SR, Cao M, He X, Li P, Hu K, Rao L, Wu SM, Xiao HB, Gao E. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. *Ann Surg Oncol* 2008; **15**: 3073-3082 [PMID: 18670822 DOI: 10.1245/s10434-008-0069-x]

57 **Bertazza L**, Mocellin S, Marchet A, Pilati P, Gabrieli J, Scalerta R, Nitti D. Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. *J Transl Med* 2009; **7**: 111 [PMID: 20028510 DOI: 10.1186/1479-5876-7-111]

58 **Qiu MZ**, Li ZH, Zhou ZW, Li YH, Wang ZQ, Wang FH, Huang P, Aziz F, Wang DY, Xu RH. Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma. *J Transl Med* 2010; **8**: 107 [PMID: 21040522 DOI: 10.1186/1479-5876-8-107]

59 **Saad AA**, Awed NM, Abd Elkerim NN, El-Shennawy D, Alfons MA, Elserafy ME, Darwish YW, Barakat EM, Ezz-Elarab SS. Prognostic significance of E-cadherin expression and peripheral blood micrometastasis in gastric carcinoma patients. *Ann Surg Oncol* 2010; **17**: 3059-3067 [PMID: 20563657 DOI: 10.1245/s10434-010-1151-8]

60 **Arigami T**, Uenosono Y, Hirata M, Yanagita S, Ishigami S, Natsugoe S. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. *Cancer Sci* 2011; **102**: 1019-1024 [PMID: 21251161 DOI: 10.1111/j.1349-7006.2011.01877.x]

61 **Cao W**, Yang W, Li H, Lou G, Jiang J, Geng M, Xi W, Ren R, Qu Q, Jin X, Zhu Y, Jin Y. Using detection of survivin-expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer. *J Surg Oncol* 2011; **103**: 110-115 [PMID: 21259243 DOI: 10.1002/jso.21777]

62 **Valladares-Ayerbes M**, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, Santamarina I, Blanco M, Fernández-Tajes J, Quindós M, Carral A, Figueroa A, Antón-Aparicio LM, Calvo L. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. *J Transl Med* 2012; **10**: 186 [PMID: 22954417 DOI: Artn]

63 **Ito H**, Inoue H, Sando N, Kimura S, Gohda K, Sato J, Murakami K, Ito S, Odaka N, Satodate H, Kudo SE. Prognostic impact of detecting viable circulating tumour cells in gastric cancer patients using a telomerase-specific viral agent: a prospective study. *BMC Cancer* 2012; **12**: 346 [PMID: 22873704 DOI: 10.1186/1471-2407-12-346]

64 **Sclafani F**, Smyth E, Cunningham D, Chau I, Turner A, Watkins D. A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers. *Clin Colorectal Cancer* 2014; **13**: 94-99 [PMID: 24332356 DOI: 10.1016/j.clcc.2013.11.003]

65 **Kubisch I**, de Albuquerque A, Schuppan D, Kaul S, Schaich M, Stölzel U. Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas. *Oncology* 2015; **89**: 294-303 [PMID: 26315108 DOI: 10.1159/000437373]

66 **Xia P**, Song CL, Liu JF, Wang D, Xu XY. Prognostic value of circulating CD133(+) cells in patients with gastric cancer. *Cell Prolif* 2015; **48**: 311-317 [PMID: 25727099 DOI: 10.1111/cpr.12175]

67 **Okabe H**, Tsunoda S, Hosogi H, Hisamori S, Tanaka E, Tanaka S, Sakai Y. Circulating Tumor Cells as an Independent Predictor of Survival in Advanced Gastric Cancer. *Ann Surg Oncol* 2015; **22**: 3954-3961 [PMID: 25777087 DOI: 10.1245/s10434-015-4483-6]

68 **Lee SJ**, Lee J, Kim ST, Park SH, Park JO, Park YS, Lim HY, Kang WK. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. *Int J Biol Markers* 2015; **30**: e382-e386 [PMID: 26044775 DOI: 10.5301/jbm.5000151]

69 **Meulendijks D**, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, Schellens JH, Grootscholten C, Tesselaar ME, Cats A. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. *Cancer* 2016; **122**: 1434-1443 [PMID: 26970343 DOI: 10.1002/cncr.29864]

70 **Li Y**, Gong J, Zhang Q, Lu Z, Gao J, Li Y, Cao Y, Shen L. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. *Br J Cancer* 2016; **114**: 138-145 [PMID: 26784122 DOI: 10.1038/bjc.2015.417]

71 **Ito H**, Sato J, Tsujino Y, Yamaguchi N, Kimura S, Gohda K, Murakami K, Onimaru M, Ohmori T, Ishikawa F, Inoue H. Long-term prognostic impact of circulating tumour cells in gastric cancer patients. *World J Gastroenterol* 2016; **22**: 10232-10241 [PMID: 28028372 DOI: 10.3748/wjg.v22.i46.10232]

72 **Pernot S**, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Bachet JB, Borg C, Ducreux M, Marcheteau E, Stanbury T, Gourgou S, Malka D, Taieb J. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. *Eur J Cancer* 2017; **79**: 15-22 [PMID: 28456090 DOI: 10.1016/j.ejca.2017.03.036]

73 **Brungs D**, Lynch D, Luk AW, Minaei E, Ranson M, Aghmesheh M, Vine KL, Carolan M, Jaber M, de Souza P, Becker TM. Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer. *World J Gastroenterol* 2018; **24**: 810-818 [PMID: 29467551 DOI: 10.3748/wjg.v24.i7.810]

74 **Bernal C**, Aguayo F, Villarroel C, Vargas M, Díaz I, Ossandon FJ, Santibáñez E, Palma M, Aravena E, Barrientos C, Corvalan AH. Reprimo as a potential biomarker for early detection in gastric cancer. *Clin Cancer Res* 2008; **14**: 6264-6269 [PMID: 18829507 DOI: 10.1158/1078-0432.CCR-07-4522]

75 **Park KU**, Lee HE, Park DJ, Jung EJ, Song J, Kim HH, Choe G, Kim WH, Lee HS. MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis. *Clin Chem Lab Med* 2009; **47**: 530-536 [PMID: 19302034 DOI: 10.1515/CCLM.2009.126]

76 **Sakakura C**, Hamada T, Miyagawa K, Nishio M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E, Chiba T, Ito K, Ito Y. Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. *Anticancer Res* 2009; **29**: 2619-2625 [PMID: 19596937]

77 **Zheng Y**, Chen L, Li J, Yu B, Su L, Chen X, Yu Y, Yan M, Liu B, Zhu Z. Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis. *Clin Biochem* 2011; **44**: 1405-1411 [PMID: 21945024 DOI: 10.1016/j.clinbiochern.2011.09.006]

78 **Ng EK**, Leung CP, Shin VY, Wong CL, Ma ES, Jin HC, Chu KM, Kwong A. Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. *PLoS One* 2011; **6**: e22233 [PMID: 21789241 DOI: 10.1371/journal.pone.0022233]

79 **Chen L**, Su L, Li J, Zheng Y, Yu B, Yu Y, Yan M, Gu Q, Zhu Z, Liu B. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. *Dis Markers* 2012; **32**: 195-202 [PMID: 22377736 DOI: 10.3233/Dma-2011-0877]

80 **Kim K**, Shin DG, Park MK, Baik SH, Kim TH, Kim S, Lee S. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. *Ann Surg Treat Res* 2014; **86**: 136-142 [PMID: 24761422 DOI: 10.4174/astr.2014.86.3.136]

81 **Hamakawa T**, Kukita Y, Kurokawa Y, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Taniguchi K, Takiguchi S, Mori M, Doki Y, Kato K. Monitoring gastric cancer progression with circulating tumour DNA. *Br J Cancer* 2015; **112**: 352-356 [PMID: 25490524 DOI: 10.1038/bjc.2014.609]

82 **Fang WL**, Lan YT, Huang KH, Liu CA, Hung YP, Lin CH, Jhang FY, Chang SC, Chen MH, Chao Y, Lin WC, Lo SS, Fen-Yau Li A, Wu CW, Chiou SH, Shyr YM. Clinical significance of circulating plasma DNA in gastric cancer. *Int J Cancer* 2016; **138**: 2974-2983 [PMID: 26815009 DOI: 10.1002/ijc.30018]

83 **Gao J**, Wang H, Zang W, Li B, Rao G, Li L, Yu Y, Li Z, Dong B, Lu Z, Jiang Z, Shen L. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. *Cancer Sci* 2017; **108**: 1881-1887 [PMID: 28677165 DOI: 10.1111/cas.13314]

84 **Zhang JY**, Chan EK, Peng XX, Lu M, Wang X, Mueller F, Tan EM. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. *Clin Immunol* 2001; **100**: 149-156 [PMID: 11465943 DOI: 10.1006/clim.2001.5048]

85 **Xu QW**, Zhao W, Wang Y, Sartor MA, Han DM, Deng J, Ponnala R, Yang JY, Zhang QY, Liao GQ, Qu YM, Li L, Liu FF, Zhao HM, Yin YH, Chen WF, Zhang Y, Wang XS. An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. *Cancer Res* 2012; **72**: 6351-6361 [PMID: 23135912 DOI: 10.1158/0008-5472.can-12-1656]

86 **Looi K**, Megliorino R, Shi FD, Peng XX, Chen Y, Zhang JY. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. *Oncol Rep* 2006; **16**: 1105-1110 [PMID: 17016600]

87 **Hoshino I**, Nagata M, Takiguchi N, Nabeya Y, Ikeda A, Yokoi S, Kuwajima A, Tagawa M, Matsushita K, Satoshi Y, Hideaki S. Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. *Cancer Sci* 2017; **108**: 308-315 [PMID: 28064445 DOI: 10.1111/cas.13158]

88 **Zhang JY**, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. *Cancer Epidemiol Biomarkers Prev* 2003; **12**: 136-143 [PMID: 12582023]

89 **Koziol JA**, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, Chan EK, Tan EM. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. *Clin Cancer Res* 2003; **9**: 5120-5126 [PMID: 14613989]

90 **Werner S**, Chen H, Butt J, Michel A, Knebel P, Holleczek B, Zörnig I, Eichmüller SB, Jäger D, Pawlita M, Waterboer T, Brenner H. Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. *Sci Rep* 2016; **6**: 25467 [PMID: 27140836 DOI: 10.1038/srep25467]

**P-Reviewer:** Aoyagi K, Surlin VM **S-Editor:** Gong ZM **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Flow chart of current and potential applications of circulating tumor cell.** Circulating tumor cells (CTCs): The blood samples from cancer patients are processed through various isolation/enrichment and detection techniques. CTCs are usually captured along with contaminating leukocytes. Various detection methods are utilized to detect the rare cell population in the bloodstream.

**Table 1 Prognostic value of circulating tumor cells in gastric cancer**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristic and number of patients** | | **Detection method** | |  | **Statistic value** | | **Ref.** |
|  | 17 | RT-PCR | CA19 mRNA | OS | *P* = 0.014 | CK19 (+) *vs* (-) | Yeh *et al*[[44](#_ENREF_44)], 1998 |
| Ⅰ-Ⅳ | 57 | RT-PCR | CEA mRNA | Liver metastasis recurrence | *P* = 0.03 | CEA (+) *vs* (-) | Miyazono *et al*[[45](#_ENREF_45)], 2001 |
| Ⅰ-Ⅳ | 106 | RT-PCR | CEA mRNA | Recurrence  /metastasis | *P* = 0.02 | CEA (+) *vs* (-) | Sumikura *et al*[[46](#_ENREF_46)], 2003 |
| Ⅰ-Ⅳ | 46 | qRT-PCR | CK20 mRNA | 2-yr-survival | *P* < 0.05 | CK20 (+) *vs* (-) | Friederichs *et al*[[47](#_ENREF_47)], 2005 |
| Ⅰ-Ⅳ | 41 | RT-PCR | CK20 mRNA | OS | *P* = 0.0363 | CK20 (+) *vs* (-) | Illert *et al*[[48](#_ENREF_48)], 2005 |
| Ⅰ-Ⅲ | 46 | RT-PCR | CEA mRNA | Recurrence | *P* ≤ 0.00022 | CEA after sugery (+)  *vs* (-) | Seo *et al*[[49](#_ENREF_49)], 2005 |
| Ⅰ-Ⅳ | 52 | RT-PCR | C-Met mRNA  MUC1 mRNA | OS  OS | *P* = 0.0178  *P* = 0.0352 | C-Met (+) *vs* (-)  MUC1 (+) *vs* (-) | Uen *et al*[[50](#_ENREF_50)], 2006 |
| Ⅰ-Ⅳ | 42 | qRT-PCR | CEA mRNA | Recurrence  /metastasis | *P* = 0.032 | CEA (+) *vs* (-) | Wu *et al*[[51](#_ENREF_51)], 2006 |
| Ⅰ-Ⅳ | 64 | MAH | hTERT/CK19/CEA/MUC1 | Recurrence  /metastasis | *P* = 0.009 | All marker (+) *vs* the  others | Wu *et al*[[52](#_ENREF_52)], 2006 |
| Ⅰ-Ⅳ | 57 | RT-PCR | CK20 mRNA | 5-year survival | *P* ＞ 0.05 | CK20 (+) *vs* (-) | Pituch-Noworolska *et al*[[53](#_ENREF_53)], 2007 |
| Metastatic | 27 | CellSearch System | EpCAM  CK8/18/19 | OS | *P* = 0.039 | CTC ≥ 2 *vs* < 2 | Hiraiwa *et al*[[54](#_ENREF_54)], 2008 |
| Ⅰ-Ⅳ | 69 | RT-PCR | CK19 mRNA  CK20 mRNA | OS  OS | *P* = 0.0347  *P* = 0.049 | CK19 (+) *vs* (-)  CK20 (+) *vs* (-) | Koga *et al*[[55](#_ENREF_55)], 2008 |
| Ⅰ-Ⅳ | 810 | RT-PCR | MT1-MMP | Recurrence  /metastasis | *P* = 0.0018 | MT1-MMP (+) *vs* (-) | Mimori *et al*[[25](#_ENREF_25)], 2008 |
| Ⅰ-Ⅳ | 55 | RT-PCR  ELISA | Survivin  mRNA | RFS | *P* = 0.026 | Survivin (+) *vs* (-) | Yie *et al*[[56](#_ENREF_56)], 2008 |
| Ⅰ-Ⅳ | 70 | qRT-PCR | Survivin  mRNA | OS | *P* = 0.036 | Survivin high *vs* low | Bertazza *et al*[[57](#_ENREF_57)], 2009 |
| Advanced | 51 (2 wk after chemotherapy)  48 (4 wk after chemotherapy) | CellSearch  system | EpCAM  CK8/18/19 | PFS ,OS (2 wk after chemotherapy)  PFS ,OS (4 wk after chemotherapy) | *P* < 0.001 | CTC ≥ 4 *vs* < 4 | Matsusaka *et al*[[24](#_ENREF_24)], 2010 |
| Ⅰ-Ⅳ | 123 | qRT-PCR | CEA mRNA | Recurrence  DFS | *P* = 0.001  *P* = 0.001 | CEA (+) *vs* (-) | Qiu *et al*[[58](#_ENREF_58)], 2010 |
| Ⅰ-Ⅳ | 30 | qRT-PCR | CK18 mRNA | RFS  OS | *P* < 0.001  *P* = 0.001 | CK18 (+) *vs* (-) | Saad *et al*[[59](#_ENREF_59)], 2010 |
| Ⅰ-Ⅳ | 95 | qRT-PCR | B7-H3 mRNA | OS | *P* = 0.046 | B7-H3 high *vs* low | Arigami *et al*[[60](#_ENREF_60)], 2011 |
| Ⅰ-Ⅳ | 98 | RT-PCR  ELISA | Survivin  mRNA | DFS | *P* < 0.001 | Survivin (+) *vs* (-) | Cao *et al*[[61](#_ENREF_61)], 2011 |
| Ⅰ-Ⅳ | 52 | qRT-PCR | miR-200c | OS  RFS | *P* = 0.016  *P* = 0.044 | miR-200c high *vs* low | Valladares-Ayerbes *et al*[[62](#_ENREF_62)], 2012 |
| Ⅰ-Ⅳ | 75 | Immunofluorescence | GFP | OS | *P* =0.0021 | CTC ≥ 5 *vs* < 5 | Ito *et al*[[63](#_ENREF_63)], 2012 |
| Ⅰ-Ⅳ | 251 | CellSearch  system | EpCAM  CK8/18/19 | OS  RFS | *P* < 0.001  *P* < 0.001 | CTC (+) *vs* (-) | Uenosono *et al*[[23](#_ENREF_23)], 2013 |
| Ⅰ-Ⅳ | 22 | CellSearch  system | EpCAM  CK8/18/19 | OS  PFS | *P* = 0.23  *P* = 0.91 | CTC ≥ 2 *vs* < 2 | Sclafani *et al*[[64](#_ENREF_64)], 2014 |
| Ⅰ-Ⅳ | 62 | qRT-PCR | KRT19/MUC1/EPCAM/CEACAM5/BIRC5 mRNA | OS  PFS | *P* = 0.003  *P* < 0.001 | All marker (+) *vs* the  others | Kubisch *et al*[[65](#_ENREF_65)], 2015 |
| Ⅰ-Ⅳ | 36 | Flow cytometry | CD133  ABCG2 | OS | *P* = 0.034 | CD133 (+) *vs* (-) | Xia *et al*[[66](#_ENREF_66)], 2015 |
| Ⅰ-Ⅳ | 136 | CellSearch  system | EpCAM  CK8/18/19 | PFS | *P* = 0.016 | CTC (+) *vs* (-) | Okabe *et al*[[67](#_ENREF_67)], 2015 |
| Ⅰ-Ⅳ | 100 | Cell Search  system | EpCAM  CK8/18/19 | OS  PFS | *P* = 0.004  *P* = 0.004 | CTC ≥ 5 *vs* < 5 | Lee *et al*[[68](#_ENREF_68)], 2015 |
| Ⅰ-Ⅳ | 24 | FACS-ICC | EpCAM | OS  PFS | *P* = 0.014  *P* = 0.007 | CTC ≥ 2 *vs* < 2 | Meulendijks *et al*[[69](#_ENREF_69)], 2016 |
| Ⅰ-Ⅳ | 136 | CellSearch  system | EpCAM  CK8/18/19 | OS  PFS | *P* < 0.001  *P* = 0.001 | CTC ≥ 3 *vs* < 3 | Li *et al*[[70](#_ENREF_70)], 2016 |
| Ⅰ-Ⅳ | 65 | Immunofluorescence | OBP-401 | OS  RFS | *P* = 0.183  *P* = 0.034 | OBP-401 (+) *vs* (-) | Ito *et al*[[71](#_ENREF_71)], 2016 |
| Ⅰ-Ⅳ | 106 | CellSearch  system | EpCAM  CK8/18/19 | OS  RFS | *P* = 0.003  *P* = 0.0002 | CTC ≥ 2 *vs* < 2 | Peront *et al*[[72](#_ENREF_72)], 2017 |
| Ⅰ-Ⅳ | 43 | IsoFlux platform | EpCAM | OS | *P* = 0.0013 | CTC ≥ 17 *vs* < 17 | Brungs *et al*[[73](#_ENREF_73)], 2018 |

qRT-PCR: Quantitative real-time polymerase chain reaction; MAH: Membrane-array hybridization; DFS: Disease-free survival; OS: Overall survival; PFS: Progression-free survival; RFS: Relapse-free survival.

**Table 2 Detection of cell-free tumor DNA in gastric cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Candidate biomarkers** | **Sample size** | **Sample type** | **Method/technology** | **Diagnostic value/outcome** | **Ref.** |
| Total cell-free DNA level b-actin | GC = 53, HC = 21 | plasma | qPCR | AUC = 0.75, *P* < 0.0001 | Sai *et al*[[31](#_ENREF_31)], 2007 |
| DNA methylation markers RPRM (Reprimo) | GC = 43, HC = 31 | GC tissues and plasma | MSP | 95.3% GC, 9.7% HC, *P* < 0.00001;  Strong correlation between methyl status in tissues and plasma | Bernal *et al*[[74](#_ENREF_74)], 2008 |
| Gene amplification MYC gene copy number (MYC/GAPDH ratio) | GC = 57, HC = 39 | tissues and plasma | qPCR | AUC = 0.816;  Strong positive correlation between MYC levels in GC tissues and plasma (*r* = 0.342; *P* = 0.009) | Park *et al*[[75](#_ENREF_75)], 2009 |
| RUNX3 | GC (preoperative) = 65, GC (postoperative) = 43, HC = 50 | tissues and serum | qMSP | AUC = 0.8651, Sn = 95.5%, Sp = 62.5%;  Decrease after surgical resection | Sakakura *et al*[[76](#_ENREF_76)], 2009 |
| KCNA4 + CYP26B1 | GC = 46, GPL = 46, HC = 30 | serum | Discovery: Methylation microarray in tissues;  Testing: MSP | AUC = 0.917, Sn = 91.3%, Sp = 92.1% | Zheng *et al*[[77](#_ENREF_77)], 2011 |
| SLC19A3 | Discovery: GC = 45, HC = 60; Validation: GC = 20, HC = 20 | plasma | MSRED-qPCR | Increased in GC, *P* < 0.0001 | Ng *et al*[[78](#_ENREF_78)], 2011 |
| Alu DNA sequences | GC = 54, HC = 59 | plasma | Alu81-qPCR | AUC = 0.784, Sn = 75%, Sp = 63% | Park *et al*[[32](#_ENREF_32)], 2012 |
| FAM5C + MYLK | GC = 58, GPL = 46, HC = 30 | serum | Discovery: MeDIP in cell lines;  Testing: MSP | AUC = 0.838, Sn = 77.6%, Sp = 90% for GC *vs* HC;  Sn = 30.4% for GPL *vs* HC; Decrease after surgical resection | Chen *et al*[[79](#_ENREF_79)], 2012 |
| XAF1 | GC = 202, HC = 88 | tumor tissues and serum | qMSP | AUC = 0.909, *P* < 0.0001;  83.9% concordance between tissues and serum | Ling *et al*[[33](#_ENREF_33)], 2013 |
| Total cfDNA level | Early GC = 16; advanced GC = 14; HC = 34 | plasma | Measurement of cfDNA concentration | AUC = 0.991, Sn = 96.67%, Sp = 94.11% for GC *vs* HC | Kim *et al*[[80](#_ENREF_80)], 2014 |
| HER2 + MYC | GC = 81; gastritis = 63; HC = 32 | plasma and tissues | FISH and qPCR | AUC = 0.850, Sn = 69%, Sp = 92% | Park *et al*[[34](#_ENREF_34)], 2014 |
| HER2 gene copy number (HER2/RPPH1 ratio) | Discovery: GC = 52 (pre and post-operative treatment), HC = 40;Validation: GC = 25 plasma | plasma and tissues | qPCR | AUC = 0.746, Sn = 53.9%, Sp = 96.7%;  Positive correlation between GC tissues and plasma (*r* = 0.424; *P* = 0.00721);  Decrease in post-treatment plasma in HER2 + GC cases; Sn = 66.7%, Sp = 100% | Shoda *et al*[[35](#_ENREF_35)], 2015 |
| TP53 | GC = 6 | plasma | Parallel sequencing | ctDNATP53 mutation in three out of six patients (50%) | Hamakawa *et al*[[81](#_ENREF_81)], 2015 |
| AKT1, AKT3, PIK3CA, PTEN, ARID1A, TP53 and BRAF | GC = 277 | plasma and tissues | MassARRAY system | 32 out of 94 patients (34%) with a tissue mutation had a corresponding mutation in plasma | Fang *et al*[[82](#_ENREF_82)], 2016 |
| HER2 | GC = 70 | plasma and tissues | dual-color ISH assay | ctDNA had a high concordance of HER2 amplification with tumor tissues(91.4%, Kappa index = 0.784, *P* < 0.001) | Gao *et al*[[83](#_ENREF_83)], 2017 |
| HER2 | GC = 60; HC = 30 | plasma and tissues | digital droplet PCR | The preoperative plasma HER2 ratio correlated with the tumor HER2 status (*P* < 0.001);  Sn = 73.3%, Sp = 93.3% | Shoda *et al*[[36](#_ENREF_36)], 2017 |

AUC: Area under the curve; GC: Gastric cancer; GPL: Gastric precancerous lesions; HC: Healthy controls; MeDIP: Methylated DNA immunoprecipitation; MSP: Methylation-specific PCR; MSRED-qPCR: Methylation-sensitive restriction enzyme digestion and real-time quantitative PCR; Sn: Sensitivity; Sp: Specificity; FISH: fluorescence in situ hybridization.

**Table 3 Detection of autoantibodies against tumor associated antigens in gastric cancer**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Biomarker signature description** | **Technology** | **Study design** | **Sample size (GC/controls)** | **Diagnostic value** | **Ref.** |
| 2 TAAs-p62 and Koc | ELISA | GC *vs* HC | 135/82 | Sn = 19.3%, Sp = 97.6%, *P* < 0.01 | Zhang *et al*[[84](#_ENREF_84)], 2001 |
| 3TAAs-IQGAP3, KRT23 and REG3A | PARSE assay | GC *vs* HC (age and sex matched) | 48/46 | Sn = 22.9%, Sp = 100%, *P* < 0.001 | Xu *et al*[[85](#_ENREF_85)], 2012 |
| 3 TAAs-p16, p53 and c-myc | ELISA | GC *vs* HC | 74/82 | Sn = 21.6%, Sp = 97.6%; *P* < 0.001 | Looi *et al*[[86](#_ENREF_86)], 2006 |
| 6 TAAs-p53, Hsp70, HCC-22-5, PrxVI, KM-HN-1 and p90 | ELISA | GC vs HC，training set  GC *vs* HC，validation set | 100/79  248/74 | Sn = 49.0%, Sp = 92.4%, *P* < 0.01  Sn = 52.0%, Sp = 90.5%, *P* < 0.01 | Hoshion *et al*[[87](#_ENREF_87)], 2017 |
| 7 TAAs - p53, C-myc, p16, IMP1, Koc, p62 and Survivin | ELISA | Cardia GC *vs* HC | 88/140 | AUC = 0.73, Sn = 64%, Sp = 87%, *P* < 0.001 | Zhou *et al*[[41](#_ENREF_41)], 2015 |
| 7 TAAs - C-myc, Cyclin B1, IMP1, Koc, P53, p62 and Survivin | ELISA, fixed cut-off  ELISA, individual cut-off | GC *vs* HC  GC *vs* HC | 91/346  91/346 | Sn = 52.7%, Sp = 89.9%, *P* < 0.01  Sn = 98.9%, Sp = 93.1%, *P* < 0.001 | Zhang *et al*[[88](#_ENREF_88)], 2003  Koziol *et al*[[89](#_ENREF_89)], 2003 |
| 45 T7 phage-displayed TAA clones (including NY-ESO-1, DDX53, MAGE antigens *etc.*) | T7 phage displayed TAA microarray | GC *vs* HC (age and  sex matched)  GC *vs* gastritis  GC *vs* gastric ulcer | T:100/100  V:235/213  235/100  235/54 | AUC = 0.79, Sn = 59%, Sp = 90%, *P* < 0.001  AUC = 0.64, Sn = 58.7%, Sp = 55%, *P* < 0.001  AUC = 0.76, Sn = 58.7%, Sp = 81.5%, *P* < 0.001 | Zayakin *et al*[[42](#_ENREF_42)], 2013 |
| 64 TAAs (including MAGEA4, CTAG1, TP53, ERBB2\_C and SDCCAG8 antigens *etc.*) | bead-based multiplex serology | GC *vs* HC  GC *vs* HC | T:155/224  V:146/97 | Sn = 0-12%, Sp = 98%; *P* ＞0.05  Sn = 32%, Sp = 87%; *P* < 0.001 | Werner *et al*[[90](#_ENREF_90)], 2016 |
| 102 TAAs (including CTAG1B/CTAG2, DDX53, IGF2BP2, TP53 and MAGEA3 antigens *etc.*) | a recombinant antigen microarray | GC *vs* HC | 829/929 | AUC = 0.60, Sn = 21%, Sp = 91%, *P* < 0.001 | Meistere *et al*[[43](#_ENREF_43)], 2017 |

AUC: Area under the curve; GC: Gastric cancer; HC: Healthy controls; ND: Not determined; Sn: Sensitivity; Sp: Specificity; TAA: Tumor associated antigen; TSA: Tumor specific antigen; T: Training; V: Validation.